Palliative chemotherapy in metastatic colorectal carcinoma: Comparison of two chemotherapeutic regimens

Anticancer Research

Volumn 16, Issue 2, 1996, Pages 921-926

  Bremnes, Roy M ^a   Wist, Erik A ^a  

^a UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

Author keywords

Metastatic colorectal carcinoma; Palliative chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; BICARBONATE; FLUOROURACIL; FOLINIC ACID; METHOTREXATE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; COLORECTAL CARCINOMA; CONJUNCTIVITIS; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; EPIPHORA; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; PRIORITY JOURNAL;

EID: 0029929854     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Cohen AM, Shank B and Friedman MA: Colorectal cancer. In: Cancer. Principles & practice of oncology (DeVita VT, Hellman S and Rosenberg SA, eds). Philadelphia, Lippincott, 1989, pp 895-964.
2. Carter SK and Friedman M: Integration of chemotherapy into combined modality treatment of solid tumors II. Large bowel carcinoma. Cancer Treat Rev 1, 11-129, 1974.
3. Lavin P, Mittelman A, Douglas H et al: Survival and response to chemotherapy for advanced colorectal carcinoma. An Eastern Cooperative Oncology Group report. Cancer 46: 1536-1543, 1980.
4. Richards F, Case LD, White DR et al. Combination chemotherapy (5-fluorouracil, methyl-CCNU, mitomycin C) versus 5-fluorouracil alone for advanced previously untreated colorectal carcinoma. A phase III study of the Piedmont Oncology Association. J Clin Oncol 4: 565-570, 1986.
5. Baker LH, Talley RW, Matter R et al: Phase III comparison of the treatment of advanced gastrointestinal cancer with bolus weekly 5-FU vs methyl-CCNU plus bolus weekly 5-FU. A Southwest Oncology Group study. Cancer 38: 1-7, 1976.
6. Martin DS, Stolfi RL, Sawyer RC et al: Application of biochemical modulation with a therapeutically inactive modulating agent in clinical trials of cancer chemotherapy. Cancer Treat Rep 69: 421-423, 1985.
7. Mini E and Bertino JR: Biochemical modulation of 5-fluorouracil by metabolites and antimetabolites In: Synergism and antagonism in chemotherapy (Chou TC and Rideout D. eds). Orlando, Academic Press Inc., 1991, pp 449-506.
8. Benz C and Cadman E: Modulation of fluorouracil metabolism and cytotoxicity by antimetabolite pretreatmcnt in human colorectal adenocarcinoma. Cancer Res 41: 994-998, 1981.
9. Bertino JR, Sawicki WL and Linquist CA: Schedule-dependent antitumor effects of methotrexate and 5-fluorouracil. Cancer Res 27: 327-328, 1977.
10. KDamon LE, Cadman E and Benz C: Enhancement of 5-fluorouracil antitumor effects by the prior administration of methotrexate. Pharmac Ther 43: 155-185, 1989.
11. Lee VT and Khwaja TA: Adjuvant postoperative chemotherapy with 5-fluorouracil and methotrexate: effect of schedule of administration on metastasis of 13762 mammary adenocarcinoma. J Surg Oncol 9: 469-479, 1977.
12. Cadman E, Heimer R and Davis L: Enhanced 5-fluorouracil nucleotide formation after methotrexate administration. Explanation for drug synergism. Science 205: 1135-1137, 1979.
13. Cadman E, Heimer R and Benz C: The influence of methotrexate pretreatment on 5-fluorouracil metabolism in L 1210 cells. J Biol Chem 256: 1695-1704, 1981.
14. Browman GP: Clinical application of the concept of methotrexate plus 5-FU sequence dependent ́synergý: how good is the evidence? Cancer Treat Rep 68: 465-469, 1984.
15. Danenberg PV and Lockskin A: Fluorinated pyrimidines as tight binding inhibitors of thymidylate synthetase. Pharmacol Ther 13: 69-90, 1981.
16. Myers CE: The pharmacology of the fluoropyrimidines. Pharmacol Rev. 33: 1-15, 1981.
17. Park JG, Collins JM, Gazdar AF et al: Enhancement of fluorinated pyrimidine-induced cytotoxicity by leucovorin in human colorectal carcinoma cell lines. J Natl Cancer Inst 80: 1560-1564, 1988.
18. Scheithauer W and Temsch EM: A study of various strategies to enhance the cytotoxic activity of 5-fluorouracil/leucovorin in human colorectal cancer cell lines. Anticancer Res 9: 1793-1798, 1989.
19. Evans RM, Laskin JD and Hakala MT: Effect of excess folates and deoxynosine on the activity and site of action of 5-fluorouracil. Cancer Res 41: 3288-3295, 1981.
20. Grem JL: Fluorinated pyrimidines. In: Cancer chemotherapy, principles & practice (Charmer BA, Collins JM, eds). Philadelphia, Lippincott, 1990, pp 180-220.
21. Martin DS, Stolfi RL and Colofiore JR: Failure of high-dose leucovorin to improve therapy with the maximally tolerated dose of 5-fluorouracil: a murine study with clinical relevance? J Natl Cancer Inst 80: 496-501, 1988.
22. Weinerman B, Maroun J, Tewart D, Cripps C and Johnston J: Sequential methotrexate. 5-fluorouracil, and leucovorin in metastatic measurable colorectal cancer. Does it work? Cancer Invest 8: 339-343, 1990.
23. Maiello E, Giotta F, Giuliani F, Naglieri E and Colucci G: Sequential methotrexate/5fluorouracil in advanced colorectal cancer treatment. J Surg Oncol 2 (suppl): 129-133, 1991.
24. Brohée D: 5-Fluorouracil (5FU) with or without folinic acid (LV) in human colorectal cancer? Multivariate analysis of the literature. Med Oncol Tumor Pharmacother 8: 271-280, 1991.
25. Einhorn L: Improvements in fluorouracil chemotherapy? J Clin Oncol 7: 1377-1379, 1989.
26. Glimelius B, Ginman C, Graffman S, Påhlman L and Stahle E: Sequential methotrexate-5-FU-leucovorin (MFL) in advanced colorectal cancer. Eur J Clin Oncol 22: 295-300, 1986.
27. Glimelius B, Hoffman K, Olafsdottir M, Påhlman L, Sjø dén P-O and Wennberg A: Quality of life during cytostatic therapy for advanced symptomatic colorectal carcinoma: a randomized comparison for two regimens. Eur J Clin Oncol 25: 829-835, 1989.
28. Kreuser ED, Hilgenfeld RU, Matthias M et al: A phase II trial of interferon α-2b with folinic acid and 5-fluorouracil administered by 4-hour infusion in metastatic colorectal carcinoma. Semin Oncol 19 (suppl 4): 57-62, 1992.
29. Kemeny N: Role of chemotherapy in the treatment of colorectal carcinoma. Sem Surg Oncol. 3: 190-214, 1987.
30. Miller AB, Hoogstraten B, Staquet M, and Winkler A: Reporting results of cancer treatment. Cancer 47: 207-214, 1981.
31. Kemeny N and Golbey R: A chemotherapeutic approach to colorectal carcinoma. In: Neoplasms of colon, rectum, and anus (Stearns MW, ed). New York, Wiley, 1980. pp 155-168.
32. Carter SK: Large bowel cancer: The current status of treatment. J Natl Cancer Inst 56: 3-10, 1976.
33. Damon LE and Cadman EC: The metabolic basis for combination chemotherapy. Pharmac Ther 38: 73-127, 1988.
34. Carlsson G, Graf W, Gustavsson BG et al: Sequential 5-fluorouracil and leucovorin in patients with advanced symptomatic gastrointestinal cancer. Eur J Cancer 26: 874-876, 1990.
35. Hart IA and Fidler, IJ: The implications of tumor heterogeneity for studies on the biology and therapy of cancer metastasis. Biochem Biophys Acta 651: 37-50, 1981.
36. Coates AS, Tattersall MHN, Swanson C et al: Combination therapy with methotrexate and 5-fluorouracil: a prospective randomized trial of order of administration. J Clin Oncol 2: 756-761, 1984.
37. Bertino JR, Mini E, and Sobrero A: Sequential methotrexate and 5-fluorouracil in the treatment of solid tumor. In: Fluoropyrimidines in cancer therapy (Kimura K, ed). Excerpta Medica, 1984, pp 251-260.
38. Mehrotra S, Rosenthal CJ and Gardner B: Biochemical modulation of antineoplastic response in colorectal carcinoma: 5-fluorouracil (F), high-dose methotrexate (M) with calcium leucovorin (L) rescue (FML) in two sequences of administration. Proc Am Soc Clin Oncol 1: 100, 1982.
39. Glimelius B: Biochemical modulation of 5-fluorouracil: a randomized comparison of sequential methotrexate, 5-fluorouracil and leucovorin versus sequential 5-fluorouracil and leucovorin in patients with advanced symptomatic colorectal cancer. Ann Oncol 4: 235-240, 1993.
40. Spears CP, Gustavsson BG and Frösing R: Folinic acid modulation of fluorouracil: kinetics of bolus administration. Invest New Drugs 7: 27-36, 1989.
41. Carlsson G, Gustavsson BG, Spears CP, and Hafström LO: 5-Fluorouracil plus leucovorin as adjuvant treatment of an experimental liver tumor in rats. Anticancer Res 10: 813-816.
42. Nobile MT, Rosso, Sertoli MR et al: Randomised comparison of weekly bolus 5-fluorouracil with or without leucovorin in metastatic colorectal carcinoma. Eur J Cancer 28: 1823-1827, 1992.
43. Rosso R, Mazzei T, Sobrero A et al: Phase II trial of 5-fluorouracil and the natural L-isomer of folinic acid in the treatment of advanced colorectal carcinoma. Eur J Cancer 30: 338-343, 1994.
44. Jodrell D, Murray L, Kaye SB and Cassidy J: Bolus/infusional (B/I) 5-fluorouracil (5-FU) and folinic acid (FA) in the treatment of metastatic colorectal carcinoma (MCCa). Proc Am Assoc Cancer Res 34: 202, 1993.
45. Tobias JS and Tattersall MHN: Doing the best for the cancer patient. Lancet Jan 5: 35-37, 1985.
46. Watson JW: What does ́responsé in cancer chemotherapy really mean? Br Med J 283: 34-37, 1981.